An HIV vaccine “lenacapavir"It's ready: the drug has completed the final stage of testing" — 99% of patients developed immunity.
During the tests lenacapavir was introduced 2179 people from the most vulnerable groups, and only two people contracted HIV. The rest received immunity.
If the results remain consistent, the FDA will approve the drug for sale as early as next year.
"Lenacapavir" – инъекционный препарат, вводимый дважды в год, на 100% эффективен в предотвращении распространения ВИЧ, согласно первым данным клинического испытания. В случае одобрения препарат предлагает еще один вариант профилактики ВИЧ и приближает весь мир на шаг к искоренению ВИЧ.
"Lenacapavir" is taken twice a year. It should not be referred to as a medication, since Lenacapavir is a pre-exposure prophylaxis (PrEP), meaning it is effective only if you are not yet infected with HIV.
What kind of study is this?
Research Purpose 1 A study involving 5,000 people was conducted at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs. It The study showed that twice-yearly injections of a new drug for pre-exposure prophylaxis provide young women with complete protection against HIV infection. During Research The study examined whether a six-month course of lenacapavir injections would provide better protection against HIV infection than two other drugs, both of which are taken as daily pills. All three drugs are used for pre-exposure prophylaxis (or PrEP).
0 comments
Enter your email — we’ll send you a one-time code. No passwords or accounts.
Code sent to
If the email doesn't appear in your inbox within a few minutes, check your spam, junk, or promotions folder, as some email services may mistakenly place automated messages there